Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 218

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 218
---
 brought against us. Because of the increasing costs
of insurance coverage, we may not be able to maintain insurance coverage at a reasonable cost or at a level adequate to satisfy liabilities
that may arise.

Business disruptions
could seriously harm our future revenue and financial condition and increase our costs and expenses. 

Our
operations, and those of CROs, contractors and consultants, could be subject to power shortages, telecommunications failures, wildfires,
water shortages, floods, earthquakes, hurricanes, typhoons, fires, extreme weather conditions, public health crises, and other natural
or man-made disasters or business interruptions for which we are predominantly self-insured. The occurrence of any of these business
disruptions could seriously harm our operations and financial condition and increase our costs and expenses. Our ability to obtain clinical
supplies of our product candidates could be disrupted if the operations of our contract manufacturers or the contract manufacturers of
our development partners are affected by a man-made or natural disaster or other business interruption.

We sell our proprietary formulations primarily
through pharmaceutical compounding facilities we own, but we may not be successful in our efforts to integrate these businesses into
our operations.

We currently have two compounding
facilities in New Jersey. We have developed “ImprimisRx” as a uniform brand for our compounding pharmaceutical business.
As we have in the past purchased and operated certain pharmaceutical compounding businesses and pharmacies and subsequently divested
or sold those associated assets, we may pursue similar strategies in the future. Those things considered, we may experience difficulties
implementing and/or executing on our compounding pharmacy strategy, including difficulties that arise as a result of our lack of experience,
and we may be unsuccessful and our plans may change materially. For instance:

    ●
    we have experienced delays and increased costs in relation to expansion
    efforts;

    ●
    we may not be able to satisfy applicable federal and state licensing
    and other requirements for any of our pharmacy businesses in a timely manner or at all;

    ●
    changes to federal and state pharmacy regulations may restrict compounding
    operations or make them more costly;

    ●
    we may be unable to achieve or maintain a sufficient physician and
    patient customer base to sustain our pharmacy operations;

    ●
    market acceptance of compounding pharmacies generally may be curtailed
    or delayed; and

    ●
    we may not be able to enter into licensing or other arrangements with
    third-party pharmacies or outsourcing facilities when desired, on acceptable terms or at